Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.45 USD | -1.80% | -0.18% | -39.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.38% | 778M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+2.91% | 22.58B | |
-14.90% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Earning Guidance for 2022